In a report issued on May 22, Christopher Marai from Nomura maintained a Buy rating on Syndax Pharmaceuticals (SNDX), with a price target of $31.00. The company’s shares closed last Friday at $16.00.
According to TipRanks.com, Marai is a 4-star analyst with an average return of 3.1% and a 50.7% success rate. Marai covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Deciphera Pharmaceuticals, and Alexion Pharmaceuticals.
Syndax Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $23.50, a 38.2% upside from current levels. In a report issued on May 8, Barclays also maintained a Buy rating on the stock with a $25.00 price target.
See today’s analyst top recommended stocks >>
Based on Syndax Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $379K and GAAP net loss of $15.24 million. In comparison, last year the company earned revenue of $379K and had a GAAP net loss of $14.3 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.